Form 4: Teva Pharmaceutical Industries Executive Receives Restricted Share Units

David R. McAvoy, EVP and Chief Legal Officer of Teva Pharmaceutical Industries, was granted 56,603 restricted share units on March 5, 2025, according to a Form 4 filing.

Summary

• David R. McAvoy, EVP and Chief Legal Officer of Teva Pharmaceutical Industries, received 56,603 restricted share units on March 5, 2025.
• These restricted share units represent a contingent right to receive one ordinary share or the cash value of one ordinary share at settlement.
• The restricted share units vest in four tranches: 14,150 on each of March 5, 2026, March 5, 2027, and March 5, 2028, and 14,153 on March 5, 2029.
• The filing was signed by Dov Bergwerk as attorney-in-fact for David R. McAvoy on March 7, 2025.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to executive compensation, and the sentiment is neutral.

Positives

• The grant of restricted share units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Granting restricted share units is a common practice in the pharmaceutical industry to incentivize and retain key executives. These grants are typically tied to performance and/or time-based vesting schedules.

Comparison to Industry Standards

• Companies like Pfizer, Johnson & Johnson, and Novartis also use restricted stock units as part of their executive compensation packages.
• The vesting schedules and amounts of these grants are generally benchmarked against peer companies to ensure competitiveness.

Stakeholder Impact

• Shareholders may view the grant positively as it aligns executive interests with long-term company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates